Previous Section
Clinical Trials
21. Results of a phase II trial testing interferon-alpha 2b and cytarabine in children and adolescents with chronic myelogenous leukemia.
- Author
- Millot F; Guilhot J; Nelken B; Leblanc T; Leverger G; Bernard F; Gandemer V; Behard C; Berger C; Cornu G; Duchene S; Guilhot F;
- Institution
- Oncology Hematology, University Hospital, Poitiers, France. f.millot@chu-poitiers.fr
- Journal
- Pediatr Blood Cancer. 2006 Oct 15;47(5):555-9.
- Abstract URL
- Click here to view abstract
22. Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate.
- Author
- Issa, Jean-Pierre J; Gharibyan, Vazganush; Cortes, Jorge; Jelinek, Jaroslav; Morris, Gail; Verstovsek, Srdan; Talpaz, Moshe; Garcia-Manero, Guillermo; Kantarjian, Hagop M;
- Institution
- Department of Leukemia and Experimental Therapeutics, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA. jpissa@mdanderson.org
- Journal
- J Clin Oncol 2005 Jun 10;23(17):3948-56. Epub 2005 May 9.
- Abstract URL
- Click here to view abstract
23. Gender aspects in chronic myeloid leukemia: long-term results from randomized studies.
- Author
- Berger, U; Maywald, O; Pfirrmann, M; Lahaye, T; Hochhaus, A; Reiter, A; Hasford, J; Heimpel, H; Hossfeld, D K; Kolb, H-J; Loffler, H; Pralle, H; Queisser, W; Hehlmann, R;
- Institution
- III. Medizinische Universitatsklinik, Fakultat fur Klinische Medizin Mannheim, Universitat Heidelberg, 68305 Mannheim, Germany. ute.bergen@med3.ma.uni-heidelberg.de
- Journal
- Leukemia 2005 Jun;19(6):984-9.
- Abstract URL
- Click here to view abstract
24. In vivo T-cell depletion with low-dose ATG is effective in reducing cGVHD after peripheral blood stem cell myeloablative sibling transplants in CML: results from a prospective phase II study.
- Author
- Bonifazi, F; Bandini, G; Stanzani, M; Palandri, F; Giannini, B; Arpinati, M; Rosti, G; Baccarani, M;
- Institution
- Journal
- Bone Marrow Transplant 2005 May;35(10):1025-6.
25. Phase I/II trial of adding semisynthetic homoharringtonine in chronic myeloid leukemia patients who have achieved partial or complete cytogenetic response on imatinib.
- Author
- Marin, David; Kaeda, Jaspal S; Andreasson, Catharina; Saunders, Sue M; Bua, Marco; Olavarria, Eduardo; Goldman, John M; Apperley, Jane F;
- Institution
- Department of Haematology, Imperial College London at Hammersmith Hospital, London, United Kingdom.
- Journal
- Cancer 2005 May 1;103(9):1850-5.
- Abstract URL
- Click here to view abstract
26. Elderly patients with Ph+ chronic myelogenous leukemia (CML): results of imatinib mesylate treatment.
- Author
- Roberto, Latagliata; Massimo, Breccia; Ida, Carmosino; Chiara, Sarlo; Enrico, Montefusco; Marco, Mancini; Antonio, Chistolini; Rosa, De Cuia; Eleonora, Russo; Giacomo, Morano Salvatore; Francesca, Biondo; Antonio, Spadea; Franco, Mandelli; Giuliana, Alimena; Fiammetta, Natalino;
- Institution
- Dipartimento di Biotecnologie Umane ed Ematologia, Universita ""La Sapienza"" di Roma, Via Benevento 6-00161, Rome, Italy. rob.lati@libero.it
- Journal
- Leuk Res 2005 Mar;29(3):287-91.
- Abstract URL
- Click here to view abstract
27. Anagrelide is effective in treating patients with hydroxyurea-resistant thrombocytosis in patients with chronic myeloid leukemia.
- Author
- Silver, R T;
- Institution
- The Leukemia and Myeloproliferative Disease Center, Division of Hematology-Oncology, Weill Medical College of Cornell University, 525 East 68th Street, New York, NY 10021, USA. rtsilve@mail.med.cornell.edu
- Journal
- Leukemia 2005 Jan;19(1):39-43.
- Abstract URL
- Click here to view abstract
Next: Immunotherapy
